StoneX Group’s Vertex Pharmaceuticals VRTX Stock Holding History

StoneX Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$662K	Sell	1,482 -715	-33%	-$333K	0.04%	350
2025 Q4	$996K	Buy	2,197 +1,642	+296%	+$708K	0.04%	352
2025 Q3	$217K	Buy	+555	New	+$232K	0.01%	799
2025 Q2	–	Sell	-682	Closed	-$331K	–	1018
2025 Q1	$331K	Buy	682 +12	+2%	+$5.59K	0.02%	595
2024 Q4	$270K	Buy	670 +14	+2%	+$6.49K	0.01%	641
2024 Q3	$305K	Sell	656 -192	-23%	-$92.2K	0.14%	212
2024 Q2	$397K	Sell	848 -30	-3%	-$13K	0.19%	148
2024 Q1	$367K	Buy	878 +113	+15%	+$47.8K	0.19%	146
2023 Q4	$311K	Buy	+765	New	+$283K	0.17%	173
2023 Q3	–	Sell	-682	Closed	-$240K	–	472
2023 Q2	$240K	Sell	682 -282	-29%	-$95K	0.14%	247
2023 Q1	$304K	Buy	964 +59	+7%	+$17.7K	0.18%	173
2022 Q4	$261K	Buy	+905	New	+$276K	0.04%	337
2017 Q3	–	Sell	-5,839	Closed	-$752K	–	354
2017 Q2	$752K	Buy	+5,839	New	+$703K	0.23%	152

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

StoneX Group's VRTX Position: Q1 2026 in Review

StoneX Group reduced its Vertex Pharmaceuticals (VRTX) stake by 33% in Q1 2026, selling an estimated $333K and leaving 1,482 shares worth $662K. The position accounts for 0.04% of the portfolio, ranked #350.

StoneX Group first reported a position in VRTX in Q2 2017 and has held it in 13 quarters since. The position peaked at $996K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

StoneX Group held 1,482 shares of Vertex Pharmaceuticals worth $662K as of Q1 2026.
StoneX Group sold 715 Vertex Pharmaceuticals shares in Q1 2026, an estimated $333K.
Vertex Pharmaceuticals made up 0.04% of StoneX Group's portfolio in Q1 2026, its #350 holding.
StoneX Group first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 13 quarters since.
StoneX Group's Vertex Pharmaceuticals position peaked at $996K in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.